Xencor, Inc Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Xencor, Inc (XNCR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $863.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-25
- Xencor, Inc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Xencor, Inc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $863.00K.
- Xencor, Inc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- Xencor, Inc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Xencor, Inc right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $863.00K, a 87.96% decline from fiscal 2024.
- Xencor, Inc right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $7.17M, a 191.06% increase from fiscal 2023.
- Xencor, Inc right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.46M, a 60.00% decline from fiscal 2022.
- Xencor, Inc right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $6.16M, a 74.40% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $863.00K derived: sum of 2 quarters · filed 2026-02-25 | $863.00K derived: sum of 3 quarters · filed 2026-02-25 | $863.00K 10-K · filed 2026-02-25 | |
| 2025-09-30 | $863.00K 10-Q · filed 2025-11-05 | $863.00K derived: sum of 2 quarters · filed 2025-11-05 | $863.00K 10-Q · filed 2025-11-05 | $863.00K derived: sum of 4 quarters · filed 2026-02-25 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $7.17M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $7.17M 10-Q · filed 2025-11-05 | $7.17M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $7.17M 10-Q · filed 2025-08-06 | $7.17M derived: sum of 3 quarters · filed 2026-02-25 | $9.63M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $7.17M 10-Q · filed 2025-05-07 | $7.17M derived: sum of 2 quarters · filed 2026-02-25 | $9.63M derived: sum of 3 quarters · filed 2026-02-25 | $9.63M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $2.46M derived: sum of 2 quarters · filed 2026-02-25 | $2.46M derived: sum of 3 quarters · filed 2026-02-25 | $2.46M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $2.46M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2025-02-24 | $2.46M derived: sum of 2 quarters · filed 2025-02-24 | $2.46M 10-Q/A · filed 2025-02-24 | ||
| 2023-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | |||
| 2023-03-31 | $0.00 10-Q/A · filed 2025-02-24 | ||||
| 2022-12-31 | $6.16M 10-K · filed 2025-02-27 | ||||
| 2022-06-30 | $1.50M 10-Q · filed 2022-08-03 | $1.50M 10-Q · filed 2022-08-03 | |||
| 2021-12-31 | $24.05M 10-K/A · filed 2025-02-24 | ||||
| 2020-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $3.03M derived: sum of 2 quarters · filed 2023-02-27 | $3.13M derived: sum of 3 quarters · filed 2023-02-27 | $3.13M 10-K · filed 2023-02-27 | $3.10M 10-K · filed 2021-02-24 |
| 2020-09-30 | $300.00K 10-Q · filed 2020-11-06 | $400.00K derived: sum of 2 quarters · filed 2020-11-06 | $400.00K 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | $100.00K 10-Q · filed 2020-08-05 | $100.00K 10-Q · filed 2020-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |